Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid Tumours

Condition:   Solid Tumour Refractory to Conventional Treatment
Interventions:   Drug: AZD6738;   Radiation: Palliative radiotherapy
Sponsors:   Royal Marsden NHS Foundation Trust;   AstraZeneca;   Cancer Research UK;   RM/ICR Biomedical Research Centre
Recruiting - verified March 2016

from #ORL via xlomafota13 on Inoreader http://ift.tt/1q5NmkT
via IFTTT